AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Follow-Up Questions
Who is the CEO of AC Immune SA?
Prof. Dr. Andrea Pfeifer is the Chief Executive Officer of AC Immune SA, joining the firm since 2003.
What is the price performance of ACIU stock?
The current price of ACIU is $2.44, it has decreased 3.17% in the last trading day.
What are the primary business themes or industries for AC Immune SA?
AC Immune SA belongs to Biotechnology industry and the sector is Health Care
What is AC Immune SA market cap?
AC Immune SA's current market cap is $245.0M
Is AC Immune SA a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for AC Immune SA, including 4 strong buy, 4 buy, 1 hold, 0 sell, and 4 strong sell
